Navigation Links
ALIMTA Helped Keep Most Common Form of Lung Cancer at Bay In Elderly Patients
Date:9/26/2011

INDIANAPOLIS, Sept. 26, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that a new subgroup analysis of data from the pivotal Phase III PARAMOUNT study showed that continuation maintenance therapy with ALIMTA® (pemetrexed for injection) also reduces the risk of disease progression in patients aged 70 years or older with advanced nonsquamous non-small cell lung cancer (NSCLC), the most common type of lung cancer.

Results from the new analysis were presented during the Lung Cancer – Metastatic Poster Session (Abstract #9072) at the 2011 European Multidisciplinary Cancer Congress (formerly known as the ECCO-ESMO Cancer Congress) in Stockholm, Sweden.

PARAMOUNT is the first study to evaluate the use of continuation maintenance therapy with ALIMTA following first-line ALIMTA plus cisplatin therapy. A total of 939 patients with advanced nonsquamous NSCLC were enrolled in the study; 539 did not progress during the induction phase and entered the maintenance phase of the trial. Of those, 92 patients were elderly.

The new analysis compared ALIMTA to placebo in elderly patients aged greater than or equal to 70 years (n=92). In the group of elderly patients, ALIMTA reduced the risk of disease progression by 65 percent (hazard ratio, 0.35; 95% CI: 0.20–0.63), based on a median progression-free survival of 6.4 months on the ALIMTA arm compared with 3.0 months on the placebo arm. In the group of patients less than 70 years of age, ALIMTA reduced the risk of disease progression by 31 percent (hazard ratio, 0.69, 95% CI: 0.54–0.90), with a progression-free survival of 4.0 months for ALIMTA and 2.8 months for placebo.

"Lung cancer can be challenging to treat in patients over 70 years of age because they often have comorbidities and may be less tolerant of anti-cancer therapies," said Cesare Gridelli, M.D., '/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
2. OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer
3. U.S. District Court Rules from Bench in Lillys Favor, Confirms Validity of Alimta Patent
4. Lung Cancer Study Reveals Similar Outcomes for African-American and Caucasian Patients Treated With Alimta®
5. ALIMTA Receives Positive Opinion From CHMP as Continuation Maintenance Therapy for Deadly Form of Lung Cancer
6. Study Shows Lantus(R) Helped People Living with Type 2 Diabetes Reach the ADAs Recommended Target for Blood Sugar Control
7. Whistleblower Doctor Comments on His Case that Helped Expose Illegal Marketing of Topamax
8. UT Southwestern Doctors Expertise Helped Trapped Chilean Miners During Pressured Half-Mile-Deep Rescue
9. Cintas ReviveR AEDs Helped Save Over 50 Lives at LA Fitness Facilities
10. Endoscopy Identified as Safe and Effective Method in Treating Common Complication of Gastric Bypass Surgery
11. Genetics Determine Optimal Drug Dose of Common Anticoagulant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Tianyin Pharmaceutical Co., Inc. (NYSE Amex: ... specializes in patented biopharmaceutical, modernized traditional Chinese medicine ... today updates the timeline for the GMP certification ... The Company is scheduled to submit the ... & Drug Administration,s (CFDA) review in the week ...
(Date:8/28/2014)... Levi & Korsinsky announces that a class ... District Court for the District of Nevada ... Therapeutics Inc. ("Galectin" or the "Company") (NasdaqCM: GALT) securities ... For more information, click here: http://zlk.9nl.com/galectin-therapeutics-galt . ... Period the Company violated federal securities laws by issuing ...
(Date:8/28/2014)... , August 28, 2014 ... titled, "DNA diagnostics Market (products, applications, techniques, end ... Opportunities, Growth and Forecast, 2013 - 2020," indicates ... $19 billion by 2020 registering a CAGR of ... provide accurate diagnosis and cost effectiveness over alternative ...
Breaking Medicine Technology:TPI Submits Dataset for GMP Inspection at Qionglai Facility (QLF) 2SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 2DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 3
... Cephalon, Inc. (Nasdaq: CEPH ) today announced ... priority review for its supplemental New Drug Application (sNDA) for ... of this year. The FDA decision on approval of NUVIGIL ... sleepiness associated with jet lag disorder due to eastbound travel ...
... , NEW YORK, Sept. 24 "Today marks ... now have evidence that it is possible to reduce the risk ... Warren, reacting to the results of the first AIDS vaccine trial ... and resources to fully analyze, understand and validate the data, but ...
Cached Medicine Technology:Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder 2Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder 3Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder 4AVAC Praises Thai AIDS Vaccine Trial Collaborators and Volunteers for Historic Study 2AVAC Praises Thai AIDS Vaccine Trial Collaborators and Volunteers for Historic Study 3AVAC Praises Thai AIDS Vaccine Trial Collaborators and Volunteers for Historic Study 4AVAC Praises Thai AIDS Vaccine Trial Collaborators and Volunteers for Historic Study 5
(Date:8/29/2014)... NZ (PRWEB) August 29, 2014 The ... Greg Allen to Chief Executive Officer effective from 1st ... Technology Officer for Winscribe. , “During this time of ... than Greg Allen,” said Matthew Weavers, Winscribe’s Founder and ... with a wealth of commercial, IT and management experience ...
(Date:8/28/2014)... VPS (Virtual Private Server) is ... into many servers, each of which has the ... dedicated computer. Top10BestSEOHosting.com has recently compared many professional ... http://www.top10bestseohosting.com/go/GoDaddy.com/ ), Bluehost and IX Web Hosting are ... The IT manager of Top10BestSEOHosting.com says, “These companies ...
(Date:8/28/2014)... 2014 When David Gergen, President of ... of Mark Brnovich, was asked to publicly support Mr. ... the Attorney General seat in the State of Arizona, ... support of Cardinal Hall of Fame wide receiver Roy ... and Mark Walczak. Green, Kennard and Walczak are members ...
(Date:8/28/2014)... Arlington, Massachusetts (PRWEB) August 29, 2014 ... company that solves some of the healthcare industry's ... design concepts that radically rethink health. Involution ... edge of technology creating software solutions for clients ... and Walgreens. , As part of the studio's ...
(Date:8/28/2014)... 28, 2014 On August 21, the ... its 2013 Annual Report, featuring the organization’s audited financial ... , According to the report, in 2013, the ... programs versus 14 cents on fundraising and administration. ... a minimum,” wrote the Foundation’s chief executive officer, Melinda ...
Breaking Medicine News(10 mins):Health News:Winscribe Names Greg Allen as CEO 2Health News:Top10BestSEOHosting.com Announces The Best Three VPS Hosting Suppliers 2Health News:Pro Player Health Alliance Back in the Political Arena 2Health News:Pro Player Health Alliance Back in the Political Arena 3Health News:Top Three Open Source Design Concepts that Rethink Health from Involution Studios 2Health News:Top Three Open Source Design Concepts that Rethink Health from Involution Studios 3Health News:Mesothelioma Applied Research Foundation’s Annual Report 2013 Release 2
... 8-year-old boy,living with epilepsy, and his mother Amy receive ... the exclusive sponsor of Canine,Assistants seizure response dogs. Through ... to play sports, take,music lessons, and learn Tae Kwon ... when his parents are not around is still a ...
... quick, non-invasive identification of the dangerous disease , , WEDNESDAY, ... be able to accurately, rapidly, and non-invasively diagnose lung ... the mouth, a new study suggests. , Oral cavity ... to be a highly accurate indicator of similar lung ...
... Mass., April 16 Xceed Molecular, a ... analysis,systems, announced that the University of Florida ... work with primary researchers,Charles Joel Rosser, MD ... of Surgery), to perform initial verification and ...
... Required to Provide Calorie Information, ALEXANDRIA, Va., ... today,s federal court ruling upholding,a New York City ... content of foods on their menus and menu ... to the regulation filed by the New York ...
... MONICA, Calif., April 16 Consumer,Watchdog today joined ... lawsuit alleging that health insurer Blue Cross engaged ... insurance of patients,after they got sick., The ... at least hundreds,of patients who have been left ...
... 16 MedCath Corporation,(Nasdaq: MDTH ) announced today ... of Directors., Mr. Grossman brings a wealth of ... Directors. He served as partner and health care,practice leader ... years with the firm. While with Pricewaterhouse Coopers, he ...
Cached Medicine News:Health News:Young Boy With Epilepsy to Gain Independence With New Seizure Response Dog From Canine Assistants 2Health News:Mouth Swab May One Day Diagnose Lung Cancer 2Health News:Mouth Swab May One Day Diagnose Lung Cancer 3Health News:Xceed Molecular Signs University of Florida to Strategic Collaborator Program; Focus on Developing New Molecular Test to Diagnose Early-Stage Bladder Cancer 2Health News:Xceed Molecular Signs University of Florida to Strategic Collaborator Program; Focus on Developing New Molecular Test to Diagnose Early-Stage Bladder Cancer 3Health News:Statement of the American Diabetes Association Supporting Federal Court's Ruling on New York City Proposal 2Health News:Consumer Watchdog Applauds L.A. City Attorney's Efforts to Reinstate Cancelled Blue Cross Patients; Urges State HMO Regulator to Do Same 2Health News:Woodrin 'Woody' Grossman Appointed to MedCath's Board of Directors 2
... Personal Micro Centrifuges MiniSpin and MiniSpin plus ... they are powerful enough so that each ... centrifuge for a wide range of molecular ... are available to meet your performance requirements. ...
Inquire...
Spectrafuge 24D High speed, digital microcentrifuge. Precision control with digital display. Easy access 24-place rotor. Set and view speed in rpm or rcf. Quiet and cool running. StripSpin adapter fo...
... Separating Power , Micromax produces forces up to ... 24 (1.5-2.0 mL) samples or 48 (0.5 mL) ... motor is designed for longevity and requires no ... In addition, all controls are microprocessor based for ...
Medicine Products: